Dilemma for cancer patients as life-saving meds are tied to vision loss

May 18, 2018 by Serena Gordon, Healthday Reporter

(HealthDay)—A newer type of cancer treatment may offer the chance of longer survival, but the drugs could also trigger new side effects, such as vision problems.

New research reports on three cases of a potentially vision-threatening eye condition called uveal effusion that developed after taking immunotherapy. Immunotherapy uses a person's own immune system to fight cancer.

Uveal effusion occurs when the eye becomes inflamed and fluid collects in the three layers that make up the wall of the eye, the researchers said. This can cause blurred vision, and even vision loss, according to the American Academy of Ophthalmology.

But though this side effect sounds worrisome, the senior author of the new research said there's no need to panic.

"No one should stop their medications," said Dr. Hakan Demirci, an associate professor of ophthalmology at the University of Michigan's Kellogg Eye Center.

"First, this is a very rare complication. The chance of developing ocular side effects or uveal effusion is very low. Second, the patients who are on this medication usually have very serious, life-threatening cancer. It is very important to keep using the medication for tumor control," he said.

And, in two of the three cases, the eye problems went away when the drug was stopped for a while. The third patient continued taking the drug, but died from his cancer.

All three patients were being treated for cancer that had spread to other parts of the body (one had lung cancer and two had melanoma). One was a 68-year-old man who had blurred vision and redness in his left eye. The second was a 52-year-old man who had redness and pain in both eyes, and the third was an 85-year-old man who had swelling in his left eye.

All three men were taking a type of immunotherapy called immune checkpoint inhibitors.

Normally, the immune system only goes after cells it recognizes as foreign. It uses molecules known as checkpoints that need to be activated or inactivated to prevent an attack on normal, healthy cells, according to the American Cancer Society (ACS).

But cancer sometimes uses these checkpoints to avoid detection by the immune system, the ACS explains. Immune checkpoint inhibitors allow the immune system to "see" the cancer hiding behind the checkpoint. If the checkpoint is turned off, the drugs may also allow the immune system to see normal cells as foreign.

Dr. Catherine Diefenbach is an American Society of Clinical Oncology expert and assistant professor of medicine at the NYU Langone Perlmutter Cancer Center in New York City.

"When you activate the immune system, you can see common and uncommon side effects," she said.

The treatments improve survival odds for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

Examples of immune checkpoint inhibitors include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), avelumab (Bavencio) and durvalumab (Imfinzi), according to the ACS.

In the three cases reported, Demirci said the began about three to eight weeks after patients received the drugs. Each received a different drug from this class of medications.

Demirci and Diefenbach both said there's no known way to prevent this side effect from happening.

"We don't know how to protect the eyes. I am sure we will figure it out as we understand more," Demirci said.

Diefenbach said it's always important to let your doctor know if you're experiencing any side effects. "If something strange is happening, let your doctor know. Don't minimize an unusual complaint," she added.

Both experts also advised patients to continue their medications until they speak with their doctor.

The case reports were published online recently in JAMA Ophthalmology.

Explore further: Ophthalmologists link immunotherapy with a serious eye condition

More information: Hakan Demirci, M.D., associate professor, ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor; Catherine Diefenbach, M.D., American Society of Clinical Oncology expert, and assistant professor of medicine, NYU Langone Perlmutter Cancer Center, New York City; April 12, 2018, JAMA Ophthalmology, online


Learn more about immunotherapy for cancer from the American Cancer Society.

Related Stories

Ophthalmologists link immunotherapy with a serious eye condition

May 7, 2018
New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

Technology holds personalised cancer vaccine breakthrough

April 10, 2018
University of Queensland researchers have developed a vaccine delivery technology that enables treatment to be tailored precisely for different cancers.

Immune therapy scores big win against lung cancer in study

April 16, 2018
For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Cancer immunotherapy found safe in patients with rheumatologic diseases

January 24, 2018
In the largest single-center study of patients with rheumatologic diseases who were prescribed modern cancer immunotherapy with what are called immune checkpoint inhibitors, only a minority of patients experienced a flare ...

Quickly spotting rare side effects from immunotherapy

January 3, 2018
Immunotherapy, which uses the body's own immune system to fight disease, is transforming the treatment of several types of cancers. Severe adverse effects can result from these groundbreaking cancer treatments, however, and ...

Recommended for you

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.